New diabetes drug shows promise in early trial
NCT ID NCT07535307
First seen Apr 20, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This early-stage study is testing a new medicine called NNC0487-0111 in 80 adults with type 2 diabetes. The goal is to see how it affects the body's use of insulin and how well the pancreas works. Participants are randomly assigned to receive either the study drug or a placebo. The results will help researchers understand if this drug could help control blood sugar better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil Institut für Stoffwechselforschung GmbH
RECRUITINGNeuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.